Comparative Pharmacology
Head-to-head clinical analysis: PERMAPEN versus TEGOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERMAPEN versus TEGOPEN.
PERMAPEN vs TEGOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Permapen (penicillin G benzathine) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
TEGOPEN is a prodrug that is converted to the active metabolite, which acts as a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), thereby increasing incretin levels (GLP-1 and GIP), enhancing glucose-dependent insulin secretion, and suppressing glucagon release.
250 mg intramuscularly every 4 weeks as a single injection.
50-100 mg/kg/day IV divided every 6-8 hours; maximum 4 g/day for adults.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-5 hours in end-stage renal disease
Terminal half-life 0.8-1.2 hours in normal renal function; prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 60-70% as unchanged drug; hepatic metabolism: ~30% to penicilloic acid; fecal: <10%
Primarily renal (70-80% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (10-15%).
Category C
Category C
Penicillin antibiotic
Penicillin antibiotic